Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | Tuvusertib and niraparib in advanced unresectable solid tumors

Timothy Yap, MBBS, PhD, FRCP, The University of Texas MD Anderson Cancer Center, Houston, TX, explores findings from a Phase I trial (NCT04170153) of tuvusertib, an oral ATR inhibitor, with niraparib in patients with metastatic or locally advanced unresectable solid tumors. Tuvusertib and niraparib, administered in a one week on and one week off schedule, showed a manageable safety profile and promising efficacy in various cancer types, including PARP inhibitor-resistant tumors. This combination will be further explored in cases resistant to PARP inhibitors in the advanced ovarian cancer setting during the D-DRAIVER Ovarian 302 trial (NCT05216250). This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.